Arbutus Biopharma Corporation filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer with common shares without par value and a business focused on chronic hepatitis B therapeutics and lipid nanoparticle intellectual property. Form 8-K reports cover financial results, FDA Fast Track designation for imdusiran, material agreements, court orders, patent proceedings involving LNP delivery technology, and licensing or settlement matters with Genevant Sciences.
The company’s proxy materials describe annual shareholder meeting matters, board governance, executive compensation, voting procedures, and related corporate approvals. Its regulatory disclosures also connect clinical and regulatory updates for imdusiran with capital-structure, risk, intellectual-property, and operating-result reporting.
Arbutus Biopharma Chief Financial Officer Tuan Nguyen reported new equity awards. On 02/02/2026, he received 73,500 restricted stock units (RSUs), each representing one common share, vesting in three equal annual installments starting one year after the grant, subject to continued service. Common shares will automatically be sold at each vesting date to cover tax withholding in a non‑discretionary way. He was also granted a stock option for 188,400 common shares at an exercise price of $4.39 per share, vesting over four years in substantially equal monthly installments beginning one month after the grant, also conditioned on continued service.
Arbutus Biopharma Corp
The RSUs vest in three equal annual installments beginning one year from the grant date, contingent on continued service, and shares will be automatically sold at vesting to cover tax withholding. She also received a stock option for 71,700 common shares at an exercise price equal to the Nasdaq closing price of $4.39 on the grant date.
This option vests over four years, with 1/48th of the shares vesting in substantially equal monthly installments starting one month after the grant date, subject to her continued service. After these grants, she directly holds 28,000 common shares and options for 71,700 shares.
Arbutus Biopharma Corporation reports that the Board of Appeal of the European Patent Office has revoked its European patent EP 2279254. The verbal decision followed oppositions filed by affiliates of Moderna and Merck and reverses earlier decisions that had upheld an amended version of this patent.
A written decision is expected in the coming months, after which Arbutus plans to petition the Enlarged Board of Appeal for review. The company states that the revocation is likely to affect its case against Moderna in Switzerland and one of its two cases against Moderna before the Unified Patent Court where this patent is asserted.
Arbutus notes that the decision rests on an EPO “added matter” standard that does not apply in the United States or other jurisdictions where it is pursuing patent infringement litigation. It does not expect the ruling to affect the potential outcome or timing of its ongoing cases against Moderna in the United States, Japan, Canada, its separate Unified Patent Court case that does not involve this patent, or its litigation against Pfizer and BioNTech in the United States.
Arbutus Biopharma Corporation filed a current report stating that its Chairperson, Chief Executive Officer and President, Lindsay Androski, is giving a presentation on the company’s ongoing patent litigation involving its lipid nanoparticle technology used in COVID-19 vaccines at Roivant Sciences Ltd.’s 2025 Investor Day. The related litigation slide deck is furnished as Exhibit 99.1 and incorporated by reference.
The company notes that these slides contain forward-looking statements about its plans and expected timing for the litigation. It cautions that these statements rely on assumptions and are subject to significant uncertainties, including risks associated with litigation generally, economic and market conditions, possible shifts in strategic focus, and the sufficiency of its cash resources. Arbutus refers readers to risk discussions in its annual and quarterly SEC reports and other continuous disclosure filings.
Arbutus Biopharma (ABUS) reported that it furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The company also made available an updated corporate presentation.
The press release is provided as Exhibit 99.1 under Item 2.02, and the corporate presentation is filed as Exhibit 99.2 under Item 8.01. Both were dated November 13, 2025 and are incorporated by reference.
Arbutus Biopharma (ABUS) filed its Q3 2025 report. Total revenue was $529,000, driven by $280,000 from collaborations and $249,000 of non-cash royalty revenue. Operating expenses were $9.2 million, reflecting lower R&D and G&A after earlier cost actions, and the company reported a net loss of $7.7 million, or $0.04 per share.
Year-to-date, revenue reached $13.0 million, primarily from recognizing $10.4 million of previously deferred revenue after terminating the Qilu license; net loss narrowed to $29.7 million. Cash, cash equivalents and marketable securities totaled $93.7 million as of September 30, 2025, with no debt, and management believes resources fund operations for at least the next 12 months. The company recorded $12.6 million of restructuring costs year-to-date tied to a 57% workforce reduction, exiting its headquarters, and discontinuing in-house research. As of November 11, 2025, 192,324,017 common shares were outstanding. Arbutus continues patent actions related to its LNP technology, with a U.S. trial against Moderna set for March 2026 and a September 2025 claim construction ruling in the Pfizer/BioNTech case that it considers favorable.
Arbutus Biopharma Corporation reported that three abstracts featuring imdusiran data and one abstract featuring AB-101 data have been accepted for poster presentations at the American Association for the Study of Liver Diseases – The Liver Meeting® 2025 in Washington, DC. The meeting is scheduled for November 7–11, 2025.
The company noted that the AB-101 abstract has been selected as a Poster of Distinction, highlighting it among the conference’s poster presentations. These details were originally shared in a press release dated October 7, 2025, which is attached as an exhibit.
Arbutus Biopharma Corporation reported that the U.S. District Court for the District of New Jersey issued a claim construction ruling in its ongoing patent lawsuit against Pfizer Inc. and BioNTech SE. The case, brought by Arbutus and its licensee Genevant Sciences, seeks damages for alleged infringement of several U.S. patents related to the manufacture and sale of Pfizer/BioNTech’s COVID-19 mRNA-based vaccines. The court’s detailed claim construction order and opinion, dated September 9, 2025, have been filed as an exhibit to this report, providing the interpretations that will guide how the patent claims are applied as the litigation continues.
Two Seas Capital and affiliated reporting persons disclosed beneficial ownership of 10,443,317 common shares of Arbutus Biopharma (symbol: ABUS), representing 5.4% of the outstanding class as of June 30, 2025. The stake is held in two funds — 7,472,841 shares in the Two Seas Global (Master) Fund and 2,970,476 shares in the Two Seas LNP Opportunities (Master) Fund — and the reporting persons state they have sole voting and sole dispositive power over all reported shares. The filing includes a certification that the securities are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The disclosure references a total share count of 191,641,511 common shares used to calculate the percentage.